<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03056599</url>
  </required_header>
  <id_info>
    <org_study_id>PRS-2</org_study_id>
    <nct_id>NCT03056599</nct_id>
  </id_info>
  <brief_title>Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma</brief_title>
  <official_title>Feasibility of Assessing Drug Response to Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Patients Undergoing Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Presage Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Presage Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study in patients with localized or metastatic soft tissue sarcoma&#xD;
      undergoing surgery to determine how sarcoma in situ responds to injected microdoses of&#xD;
      anti-cancer therapeutics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, pilot study designed to test the feasibility of using the CIVO&#xD;
      (Comparative In Vivo Oncology) system in patients with soft tissue sarcoma accessible for&#xD;
      percutaneous injection. Patients who are scheduled for surgical biopsy or tumor resection&#xD;
      surgery will be injected 4 to 72 hours prior to surgery using the CIVO device. Minute volumes&#xD;
      (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will&#xD;
      be percutaneously injected in a columnar fashion through each of 8 needles into a single&#xD;
      solid tumor. Following the patient's biopsy surgery or tumor resection surgery, the injected&#xD;
      portion and a small uninjected portion will be used to determine the in situ drug response in&#xD;
      the tumor. None of the data from this evaluation will be shared with patients or used to make&#xD;
      clinical decisions. Study clinicians will have access to the patient's health record for 1&#xD;
      year after the study to monitor patient treatment responses. Such information will be used to&#xD;
      help evaluate the correlation between clinical response and tumor response assessed via CIVO.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2016</start_date>
  <completion_date type="Actual">September 22, 2021</completion_date>
  <primary_completion_date type="Actual">July 22, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of fraction of cells positive for apoptosis and drug target engagement biomarkers around injected drugs</measure>
    <time_frame>4-72 hours after microinjection</time_frame>
    <description>Analysis will be performed to determine if there is a difference in responses caused by each drug versus the vehicle control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events related to pain</measure>
    <time_frame>up to 28 days after microinjection</time_frame>
    <description>Relationship of AE to study device or study procedure will be determined using an AE Relatedness Grading System.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coefficient of variation and intra-class correlation coefficient of fraction of cells around injected drug in multiple tumor planes</measure>
    <time_frame>4-72 hours after microinjection</time_frame>
    <description>Analysis will be performed for fraction of cells positive for apoptosis and drug target engagement biomarkers</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Soft Tissue Sarcoma Adult</condition>
  <arm_group>
    <arm_group_label>Multiple drug microinjection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected 4 to 72 hours prior to surgery using the CIVO device. Minute volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will be percutaneously injected in a columnar fashion through each of 8 needles into a single enlarged solid tumor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple drug microinjection</intervention_name>
    <description>This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.</description>
    <arm_group_label>Multiple drug microinjection</arm_group_label>
    <other_name>Doxorubicin</other_name>
    <other_name>Docetaxel</other_name>
    <other_name>Gemcitabine</other_name>
    <other_name>Interferon gamma</other_name>
    <other_name>Pembrolizumab</other_name>
    <other_name>Ipilimumab</other_name>
    <other_name>Interferon alfa-2B</other_name>
    <other_name>Bortezomib</other_name>
    <other_name>Aldesleukin</other_name>
    <other_name>Trabectedin</other_name>
    <other_name>Eribulin</other_name>
    <other_name>Olaratumab</other_name>
    <other_name>Atezolizumab</other_name>
    <other_name>Durvalumab</other_name>
    <other_name>Avelumab</other_name>
    <other_name>Nivolumab</other_name>
    <other_name>Larotrectinib</other_name>
    <other_name>Entrectinib</other_name>
    <other_name>Avapritinib</other_name>
    <other_name>Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CIVO device</intervention_name>
    <description>Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO device in soft tissue sarcoma patients undergoing surgery.</description>
    <arm_group_label>Multiple drug microinjection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or over.&#xD;
&#xD;
          -  At least one suspected soft tissue sarcoma tumor that is considered by the&#xD;
             investigator to be: (1) accessible for percutaneous injection and (2) at least 2.5 cm&#xD;
             in shortest dimension for patients undergoing an incisional biopsy, or at least 3 cm&#xD;
             in shortest dimension for patients undergoing an excisional biopsy/tumor resection.&#xD;
             Tumors should not be selected if the Investigator believes them to be necrotic or&#xD;
             exhibit signs of radiation-induced fibrosis.&#xD;
&#xD;
          -  Prior surgical evaluation and plan for surgical biopsy or surgery to remove the tumor&#xD;
             being injected.&#xD;
&#xD;
          -  ECOG performance status of 0-2 (or a Karnofsky performance status of &gt;50%)&#xD;
&#xD;
          -  Labs required for enrollment (prior to microinjection):&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1000/mm3&#xD;
&#xD;
               -  Platelet count &gt; 50,000/mm3&#xD;
&#xD;
               -  Hematocrit &gt; 25%&#xD;
&#xD;
               -  Creatinine &lt;3.0 mg/dl&#xD;
&#xD;
               -  Total Bilirubin &lt;4.0 mg/dl&#xD;
&#xD;
               -  Bilirubin &lt;4.0 mg/dl, SGOT ≤ 1.5 times the upper limit of normal&#xD;
&#xD;
               -  PT and PTT ≤ 1.5 times the upper limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with active fungal, viral, or bacterial infections.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Inability to give informed consent.&#xD;
&#xD;
          -  Current treatment with anticoagulation such as warfarin or low-molecular-weight&#xD;
             heparin.&#xD;
&#xD;
          -  Tumors near critical structures such as those located near or in the brain or spine.&#xD;
             This assessment will be determined by the treating clinician.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Deutsch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Gundle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health &amp; Science University (OHSU)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seth Pollack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/SCCA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monter Cancer Center (Northwell Health)</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance (SCCA)/University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 22, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2017</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>in vivo drug sensitivity</keyword>
  <keyword>personalized medicine</keyword>
  <keyword>precision oncology</keyword>
  <keyword>in vivo oncology</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>microinjection</keyword>
  <keyword>microdosing</keyword>
  <keyword>tumor microenvironment</keyword>
  <keyword>multiplexed immunohistochemistry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Avelumab</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
    <mesh_term>Olaratumab</mesh_term>
    <mesh_term>Entrectinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

